Ipsen Sa Adr Company Profile (OTCMKTS:IPSEY)

About Ipsen Sa Adr (OTCMKTS:IPSEY)

Ipsen Sa Adr logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:IPSEY
  • CUSIP: N/A
  • Web: www.ipsen.com
Capitalization:
  • Market Cap: $10.68 billion
  • Outstanding Shares: 329,748,000
Average Prices:
  • 50 Day Moving Avg: $33.44
  • 200 Day Moving Avg: $26.79
  • 52 Week Range: $15.22 - $35.71
P/E:
  • Trailing P/E Ratio: 41.34
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.92 billion
  • Price / Sales: 5.56
  • Book Value: $4.73 per share
  • Price / Book: 6.85
Profitability:
  • EBIDTA: $444.08 million
Debt:
  • Current Ratio: 1.87%
  • Quick Ratio: 1.67%
Misc:
  • Average Volume: 967 shs.
 
Frequently Asked Questions for Ipsen Sa Adr (OTCMKTS:IPSEY)

What is Ipsen Sa Adr's stock symbol?

Ipsen Sa Adr trades on the OTCMKTS under the ticker symbol "IPSEY."

How often does Ipsen Sa Adr pay dividends? What is the dividend yield for Ipsen Sa Adr?

Ipsen Sa Adr declared a None dividend on Friday, July 7th. Stockholders of record on Monday, June 12th will be given a dividend of $0.175 per share on Tuesday, July 11th. The ex-dividend date is Thursday, June 8th. View Ipsen Sa Adr's Dividend History.

Who are some of Ipsen Sa Adr's key competitors?

How do I buy Ipsen Sa Adr stock?

Shares of Ipsen Sa Adr can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ipsen Sa Adr's stock price today?

One share of Ipsen Sa Adr stock can currently be purchased for approximately $32.39.


MarketBeat Community Rating for Ipsen Sa Adr (OTCMKTS IPSEY)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about Ipsen Sa Adr and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ipsen Sa Adr (OTCMKTS:IPSEY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ipsen Sa Adr (OTCMKTS:IPSEY)
Show:
DateFirmActionRatingPrice TargetDetails
7/7/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralView Rating Details
5/9/2016Morgan StanleyUpgradeEqual Weight -> OverweightView Rating Details
4/26/2016Jefferies Group LLCUpgradeHold -> BuyView Rating Details
3/8/2016Barclays PLCDowngradeOverweight -> Equal WeightView Rating Details
2/18/2016Societe GeneraleInitiated CoverageBuyView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Ipsen Sa Adr (OTCMKTS:IPSEY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Ipsen Sa Adr (OTCMKTS:IPSEY)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Current Dividend Information for Ipsen Sa Adr (OTCMKTS:IPSEY)
Most Recent Dividend:7/11/2017
Annual Dividend:$0.17
Dividend Yield:0.52%
Payout Ratio:
Dividend Payments by Quarter for Ipsen Sa Adr (OTCMKTS:IPSEY)

Dividend History by Quarter for Ipsen Sa Adr (OTCMKTS IPSEY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/7/2017None$0.186/8/20176/12/20177/11/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Ipsen Sa Adr (OTCMKTS:IPSEY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Ipsen Sa Adr (OTCMKTS:IPSEY)
Latest Headlines for Ipsen Sa Adr (OTCMKTS:IPSEY)
Source:
DateHeadline
finance.yahoo.com logoIpsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017
finance.yahoo.com - July 27 at 1:17 AM
finance.yahoo.com logoIpsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy
finance.yahoo.com - July 22 at 1:58 AM
finance.yahoo.com logoIpsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors
finance.yahoo.com - July 3 at 7:06 AM
finance.yahoo.com logoIpsen Announces Co-Promotion Agreement With Saol Therapeutics To Promote Dysport® (abobotulinumtoxinA) in the United States
finance.yahoo.com - June 30 at 8:05 PM
americanbankingnews.com logoIpsen Sa Adr (IPSEY) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 27 at 11:28 PM
finance.yahoo.com logoIpsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma
finance.yahoo.com - June 19 at 4:59 PM
streetinsider.com logoIpsen Biopharmaceuticals Announces FDA Approval of Dysport
www.streetinsider.com - June 17 at 11:29 PM
americanbankingnews.com logoIpsen Sa Adr (IPSEY) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 17 at 12:32 AM
finance.yahoo.com logoIpsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
finance.yahoo.com - June 16 at 6:50 PM
finance.yahoo.com logoIpsen initiates share buy-back program to cover its free performance share allocation plan
finance.yahoo.com - June 8 at 6:25 AM
finance.yahoo.com logoCombined Shareholders’ Meeting of IPSEN S.A. Held on 7 June 2017
finance.yahoo.com - June 7 at 5:33 PM
finance.yahoo.com logoIpsen Announces New Data to Be Presented at ASCO in Line with Its Continued Commitment to Oncology Research
finance.yahoo.com - June 1 at 3:23 PM
finance.yahoo.com logoIpsen Completes Acquisition of Select Consumer Healthcare Products from Sanofi
finance.yahoo.com - May 12 at 1:46 PM
finance.yahoo.com logoIpsen Presents Its New Strategy and Improved 2020 Financial Targets
finance.yahoo.com - May 12 at 1:46 PM
finance.yahoo.com logoIpsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer
finance.yahoo.com - April 14 at 9:24 AM
seekingalpha.com logoMidcap Biopharma Stocks Pick Up In The First Quarter
seekingalpha.com - April 7 at 5:51 PM
capitalcube.com logoIpsen SA :IPSEY-US: Earnings Analysis: For the six months ended December 31, 2016 : April 3, 2017
us.rd.yahoo.com - April 4 at 4:12 AM
uk.finance.yahoo.com logoIpsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
uk.finance.yahoo.com - April 3 at 5:16 PM
americanbankingnews.com logoIPSEN (IPSEY) Raised to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - April 3 at 8:02 AM
americanbankingnews.com logoZacks Investment Research Upgrades IPSEN (IPSEY) to "Strong-Buy"
www.americanbankingnews.com - March 29 at 1:00 AM
businesswire.com logoThe Ipsen Group Publishes Its 2016 Registration Document
www.businesswire.com - March 28 at 5:34 PM
seekingalpha.com logoUCB Needs Clinical Success To Drive Upside
seekingalpha.com - March 21 at 5:55 PM
finance.yahoo.com logoIpsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment …
finance.yahoo.com - March 14 at 10:12 PM
us.rd.yahoo.com logoIpsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Patients with Cervical Dystonia and Adult Upper Limb Spasticity
us.rd.yahoo.com - March 14 at 11:47 AM
uk.finance.yahoo.com logoIpsen announces MHRA1 approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer
uk.finance.yahoo.com - March 13 at 10:50 AM
uk.finance.yahoo.com logoIpsen Announces Data Presentations of Lanreotide (Somatuline® Autogel®), Telotristat Ethyl and the Investigational Compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 Conference
uk.finance.yahoo.com - March 9 at 7:19 AM
uk.finance.yahoo.com logoIpsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care
uk.finance.yahoo.com - March 2 at 3:28 PM
finance.yahoo.com logoUPDATE 1-FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug
finance.yahoo.com - February 28 at 6:06 PM
seekingalpha.com logoIpsen's (IPSEY) CEO David Meek on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 25 at 12:15 AM
uk.finance.yahoo.com logoIpsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017
uk.finance.yahoo.com - February 23 at 4:14 AM
sg.finance.yahoo.com logoDrugmaker Ipsen to buy some products from Sanofi for 83 million euros
us.rd.yahoo.com - February 13 at 11:07 AM
us.rd.yahoo.com logo3:27 am Ipsen S.A. to acquire 5 of Sanofi's (SNY) Consumer Healthcare Products for EUR83 mln
us.rd.yahoo.com - February 13 at 11:07 AM
fool.com logoIs Merrimack Pharmaceuticals Worth Stashing in Portfolios?
www.fool.com - February 12 at 5:49 PM
finance.yahoo.com logoIpsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the Association of Academic Physiatrists
finance.yahoo.com - February 9 at 6:54 PM
uk.finance.yahoo.com logoIpsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
uk.finance.yahoo.com - January 31 at 4:41 AM
uk.finance.yahoo.com logoIpsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises
uk.finance.yahoo.com - January 20 at 5:49 AM
seekingalpha.com logoIpsen to acquire oncology assets from Merrimack
seekingalpha.com - January 9 at 4:45 PM
thestreet.com logoMerrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen
www.thestreet.com - January 9 at 4:45 PM
investopedia.com logoMerrimack Pharma to Sell Cancer Drugs for $1B
www.investopedia.com - January 9 at 4:45 PM
us.rd.yahoo.com logoMerrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus
us.rd.yahoo.com - January 8 at 10:43 PM
uk.finance.yahoo.com logoIpsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
us.rd.yahoo.com - January 8 at 10:43 PM
us.rd.yahoo.com logoFrance's Ipsen to buy some Merrimack assets for up to $1 bln
us.rd.yahoo.com - January 8 at 10:43 PM
finance.yahoo.com logoFrance's Ipsen to buy some Merrimack assets for up to $1 billion
finance.yahoo.com - January 8 at 10:43 PM
finance.yahoo.com logoExelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada
au.finance.yahoo.com - December 21 at 8:42 AM
uk.finance.yahoo.com logoIpsen Announces Its Corporate Agenda for 2017
uk.finance.yahoo.com - December 13 at 10:16 AM
uk.finance.yahoo.com logoClaude Bertrand to Step Down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen
uk.finance.yahoo.com - December 12 at 10:50 AM
finance.yahoo.com logoIPSEN webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
finance.yahoo.com - November 21 at 10:48 AM
finance.yahoo.com logoIPSEN to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 16th, 2016
finance.yahoo.com - November 10 at 5:09 PM
finance.yahoo.com logoIpsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society
finance.yahoo.com - October 26 at 5:44 PM
uk.finance.yahoo.com logoIpsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year Guidance
uk.finance.yahoo.com - October 26 at 8:53 AM

Social

Chart

Ipsen Sa Adr (IPSEY) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff